EasyM™ is a non-invasive and highly sensitive, mass spectrometry-based M-protein monitoring test for patients with Multiple Myeloma (MM). EasyM™ identifies the patient’s unique M-protein peptide sequence (a biomarker for MM) and follows this unique sequence to quantify the change in M-...
blooddiagnosiscase-control studiesinflammatorymultiple myelomaprimary careBackgroundKoshiaris, ConstantinosVan den Bruel, AnnOke, Jason L.Nicholson, Brian D.Shephard, ElizabethBraddick, MickHamilton, WilliamUniv Oxford Nuffield Dept Primary Care Hlth Sci Radcliffe Primary Care Bldg Woodstock Rd Oxford...
Presenting signs and symptoms of multiple myeloma (MM) include bone pain, pathologic fractures, weakness, anemia, infection (often pneumococcal), hypercalcemia, spinal cord compression, and renal failure. In approximately 30% of cases, MM is discovered through routine blood screening when patients are...
Multiple myeloma (MM) is a plasma cell malignancy in which monoclonal plasma cells proliferate in bone marrow, resulting in an overabundance of monoclonal paraprotein (M protein), destruction of bone, and displacement of other hematopoietic cell lines. [1] First described in 1848, MM is part of...
The immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide are highly effective treatments for multiple myeloma. However, virtually all patients eventually relapse due to acquired drug resistance with resistance-causing genetic alterations being fo
In the MASTER study (NCT03224507), daratumumab+carfilzomib/lenalidomide/dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly diagnosed multiple myeloma (NDMM). In GRIFFIN (NCT02874742), daratumumab+lenalidomide/bortezomib/de
Case: A 54-Year-Old Woman with Newly Diagnosed Multiple Myeloma (NDMM)Clinical Presentation: FH is a 54-year-old woman who presents to her physician with complaints of back pain, fatigue, nausea, constipation, and occasional, but recurring dizziness...
Sixty-three new untreated patients with multiple myeloma under the age of 70 years received C-VAMP induction treatment followed by high-dose intravenous melphalan (200 mg m(-2)) and autologous stem cell transplant, either with marrow [autologous bone marrow transplants (ABMT), n = 26] or wit...
C. et al. Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma. Blood 139, 137–142 (2022). Article Google Scholar Liebers, N. et al. Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients. Blood 139, ...
Venetoclax in combination with daratumumab and dexamethasone elicits deep, durable responses in patients with t(11;14) relapsed/refractory multiple myeloma: updated analyses of minimal residual disease negativity in phase 1/2 study. Blood. 2023;142(suppl 1):338....